



NEXUS Surgical And Medicare Limited

Regd. Address: Gala No. 4, Building No. 1, Saarthak, Square Ind Park, Sativali,
Vasai (East), Palghar - 401 208. | Tel.: 8433598185 | Email: nexuscomm92@gmail.com
Website: www.nexusmed.co.in | CIN: L33100MH1992PLC328367

Date: 30th May, 2025

To,
BSE Limited
Corporate Relation Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Script Code - 538874

Sub.: Outcome of Board Meeting held on Friday, 30th May, 2025

Dear Sir / Madam,

We would like to inform you that the meeting of the Board of Directors of **Nexus Surgical and Medicare Limited** was held on **Friday, 30th May, 2025 at 04:30 p.m.** at the Registered Office of the Company situated at Gala No. 4, Saarthak, Building No. 1, Square Industrial Park, Tungarphata, Vasai (East), Palghar - 401 208 and transacted the following business:

1. The Board of Directors of the Company has approved the Audited Financial Results of the Company for the quarter and year ended 31st March, 2025. A copy of the same alongwith Auditors Report and Declaration regarding Audit Report with unmodified opinion is enclosed herewith;
2. The Board of Directors of the Company has appointed M/s. Abhilasha Chaudhary & Associates, Practicing Company Secretary, Mumbai as the Secretarial Auditors of the Company for the financial year 2024-25.

The meeting commenced at 04:30 p.m. and concluded at 06:20 p.m.

Kindly take the same on your records.

Thanking you.

Yours faithfully,

For Nexus Surgical and Medicare Limited

Ram Swaroop Joshi

DIN: 07184085

Managing Director

Encl.: as above

Nexus Surgical and Medicare Limited

Statement of Financial Results for the quarter and year ended March 31, 2025

(Rs. in lakhs, except equity per share data)

Particulars	Quarter ended on			Year ended	
	March 31, 2025 (Audited)	Dec 31, 2024 (Unaudited)	March 31, 2024 (Audited)	March 31, 2025 (Audited)	March 31, 2024 (Audited)
Income:					
Sales and Services	148.19	148.39	59.80	572.09	347.42
Other Income	0.73	-	(0.46)	0.73	2.68
Total Income	148.92	148.39	59.33	572.83	350.11
Expenses					
Purchase of stock-in-trade	42.38	63.30	41.60	189.77	92.51
Change in inventories of stock-in-trade	23.09	(33.89)	(20.04)	(2.66)	(33.15)
Employee benefits expense	25.42	4.87	5.94	40.67	23.99
Depreciation and amortization expense	0.09	0.10	0.06	0.39	0.19
Other expense	45.83	98.83	23.49	277.86	237.49
Total Expenses	136.80	133.21	51.05	506.04	321.04
Profit/(loss) before Exceptional Item and Tax	12.12	15.17	8.29	66.79	29.07
Exceptional Item Income/(Loss)	-	-	-	-	-
Profit/(loss) before Tax	12.12	15.17	8.29	66.79	29.07
Current Tax	3.24	3.82	2.47	17.00	7.70
Tax for earlier years	(0.05)	-	(0.08)	(0.05)	(0.08)
Deferred Tax	0.10	-	0.06	0.10	0.12
Tax expenses	3.29	3.82	2.45	17.05	7.74
Profit/(loss) for the period	8.83	11.36	5.84	49.74	21.33
Other comprehensive income (OCI), net of income tax					
Items that will not be reclassified to profit or loss	-	-	-	-	-
Items that will be reclassified to profit or loss	-	-	-	-	-
Total other comprehensive income, net of income tax	-	-	-	-	-
Total other comprehensive income for the period	8.83	11.36	5.84	49.74	21.33
Paid-up Equity Share Capital (Equity shares of Rs. 10 each)	547.19	547.19	547.19	547.19	547.19
Reserve excluding revaluation reserves				(440.83)	(490.56)
Basic and Diluted Earning Per Share (not annualized)	0.16	0.21	0.11	0.91	0.39

Nexus Surgical and Medicare Limited

Notes:

- 1 The above standalone financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting standards) Rules as amended from time to time and other relevant provisions of the Act.
- 2 The above standalone financial results have been reviewed and recommended by the Audit Committee and have been approved and taken on record by the Board of Directors at its meeting held on May 30, 2025.
- 3 The audit as required under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been completed by the auditors of the Company.
- 4 The Company is engaged primarily in the trading business and accordingly there are no separate reportable segments as per Ind AS 108 dealing with Operating Segment.
- 5 The company has not received any shareholder / investors complaints during the quarter ended March 31, 2025.
- 6 The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year upto March 31, 2025 and the unaudited published year-to-date figures up to December 31, 2024, being the date of the end of the third quarter of the financial year which was subjected to limited review.
- 7 The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

Nexus Surgical and Medicare Limited

Note 8 : Balance Sheet as at March 31, 2025

Particulars	(Rs. in lakhs)	
	As at March 31,	
	2025 Audited	2024 Audited
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	2.40	2.08
(b) Deferred Tax Assets (Net)	0.71	0.81
(c) Other non current assets	-	2.56
Current assets		
(a) Inventories	42.90	40.24
(b) Financial Assets:		
(i) Trade receivables	133.77	75.23
(ii) Cash and cash equivalents	33.13	23.41
(iii) Loans and Advances	-	10.28
(iv) Other Financial Assets	4.25	4.25
(c) Other current Assets	10.30	21.75
Total Assets	227.45	180.62
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	547.19	547.19
(b) Other Equity	(440.83)	(490.56)
LIABILITIES		
Current liabilities		
(a) Financial Liabilities		
(i) Trade payables	117.76	123.73
(b) Other current liabilities	3.33	0.27
Total Equity and Liabilities	227.45	180.62

Nexus Surgical and Medicare Limited

Note 9 : Cash Flows statement for the year ended March 31, 2025

Particulars	(Rs. in lakhs)	
	For the year ended March 31,	
	2025	2024
Profit before tax	66.79	29.07
Adjustments for:		
Depreciation expenses	0.39	0.19
Operating profit before working capital changes	67.18	29.26
Changes in :		
Trade receivables	(58.53)	(70.90)
Income Tax Assets	(14.44)	(9.96)
Inventories	(2.66)	(33.15)
Other Assets	21.73	(24.46)
Trade payables	(5.97)	67.93
Other financial & other liabilities	3.06	(0.19)
Cash generated from operating activities	10.37	(41.48)
Income Tax Paid	(0.05)	(0.08)
Net Cash generated from operating activities	10.42	(41.40)
Cash flow from investing activities		
Assets Purchase	(0.71)	(0.30)
Net Cash generated from investing activities	(0.71)	(0.30)
Cash flow from financing activities		
	-	-
Net cash generated	9.71	(41.70)
Cash & cash equivalents at the beginning of the year	23.41	65.11
Cash & cash equivalents at the end of the year	33.13	23.41

Reconciliation of cash and cash equivalents as per the cash flow statement

Cash and cash equivalents as per above comprise of the following

	March 31, 2024	March 31, 2023
Cash and cash equivalents	33.13	23.41
Balances per statement of cash flows	33.13	23.41

For and on behalf of Board of Directors of
Nexus Surgical and Medicare Limited

Ram Swaroop Joshi
Managing Director
DIN: 07184085

Vasai
May 30, 2025



Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Nexus Surgical and Medicare Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly and annual financial results of **Nexus Surgical and Medicare Limited** ("the company") for the quarter and year ended 31st March 2025, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India, of the net profit, other comprehensive income and other financial information for the quarter and year ended 31st March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year-to-date standalone financial results have been prepared on the basis of standalone Ind AS annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from



fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Standalone Financial Results includes the results for the quarter ended 31st March, 2025 being the balancing figures between the audited figures in respect of full financial

Office: 505, Goyal Trade Center, Sona Cinema, Shantivan, Borivali (E), Mumbai-400 066.

Tel.: 2897 6621 Email: spnatani@gmail.com Web.: www.casprnatani.in



Satya Prakash Natani & Co.

CHARTERED ACCOUNTANTS

CA SATYA PRAKASH NATANI
DISA(ICAI),FAFD

CA SANGEETA PAREKH

CA SURESHKUMAR YADAV

CA ARCHANA JAIN

CA ANU OSWAL

year ended 31st March, 2025 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our report on the statement is not modified in respect of this matter.

For and on behalf of
Satya Prakash Natani & Co.
Chartered Accountants
Firm's Registration No.: 115438W

Mumbai
Date: May 30, 2025
UDIN No.: 25048091BMKQLY4946

Satya Prakash Natani
Partner
Membership No.: 048091

Office: 505, Goyal Trade Center, Sona Cinema, Shantivan, Borivali (E), Mumbai-400 066.
Tel.: 2897 6621 Email: spnatani@gmail.com Web.: www.casprnatani.in

Branch: D-306, Navyug CHS Ltd, Goregaon Check Naka, W.E.Highway,
Goregaon (E), Mumbai-400 063. Email : suresh.yadav310@gmail.com

Branch: 112,KothariMilestone, S.V.Road, Near Malad Shopping Centre,
Malad (W), Mumbai-400 064. Email : anuparakh@gmail.com



NEXUS Surgical And Medicare Limited

Regd. Address: Gala No. 4, Building No. 1, Saarthak, Square Ind Park, Sativali,
Vasai (East), Palghar - 401 208. | Tel.: 8433598185 | Email: nexuscomm92@gmail.com
Website: www.nexusmed.co.in | CIN: L33100MH1992PLC328367

Date: 30th May, 2025

To,
BSE Limited
Corporate Relation Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Script Code - 538874

Ref.: Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub.: Declaration in respect of Auditors Report with unmodified opinion on the Audited Financial Results for the financial year ended 31st March, 2025

Dear Sir / Madam,

Pursuant to the provisions of Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 vide notification no. SEBI/LAD-NRO/GN/2016-17/001 dated 25th May, 2016; we hereby declare and confirm that the Statutory Auditors of the Company, M/s. Satya Prakash Natani & Co., Chartered Accountants, Mumbai (Registration No. 115438W) have issued an Audit Report with unmodified / unqualified opinion on the Audited Financial Results of the Company for the financial year ended 31st March, 2025.

Kindly take the same on your records.

Thanking you.

Yours faithfully,

For Nexus Surgical and Medicare Limited

Ram Swaroop Joshi

DIN: 07184085

Managing Director